The sensor is inserted by an Eversense Inserter in the upper arm and continuously measures glucose for up to 6 months.
Apple has implemented two new features in iOS 17 that will affect your experience with the Eversense CGM System.
StandBy Mode, when enabled, activates the iPhone lock screen when the phone is charging and on its side. StandBy mode affects the Eversense App's ability to provide alerts in all the ways you expect. If StandBy mode is used, be sure you have turned on Show Notifications in Settings > StandBy. On-body vibe alerts from the transmitter are not impacted.
Assistive Access Mode, when enabled, provides a cognitive accessibility feature that will change the way you access the Eversense app and changes how alerts are presented when the app is not open. On-body vibe alerts from the transmitter are not impacted, however, this feature may result in brief, intermittent interference with the transmitter's Bluetooth connection to your phone. To download, install and create an Eversense Account, Assistive Access Mode must be turned off. Once the account is created, the Eversense App may be added to Assistive Access Mode.
You should disable automatic updates to your mobile device. Some operating system updates may result in a need for a supporting update to the Eversense Mobile App. Once we have verified compatibility of new operating systems with Eversense, our compatibility page will be updated.
Eversense gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by an Eversense Inserter. The smart transmitter sits above the sensor, sending glucose data to your app.
1 sensor for 6 months of real-time glucose readings
Easy-on, easy-off smart transmitter allows you to take a break when needed*
Mild, silicone-based adhesives, changed daily
Exceptional accuracy, notably during high and low events
While all CGM systems use transcutaneous sensors that are inserted into the skin and last 7-14 days, the Eversense sensor is inserted completely under the skin. The Eversense CGM system lasts up to 6 months — eliminating the hassle and discomfort of frequent sensor insertions. Simply put, it makes managing your diabetes so much easier.
A Diabetes Therapy Associate will be in touch shortly, but if you want to reach out sooner, please call 1-945-221-9068.
To help expedite benefits verification, please have your doctor and insurance information handy.
We will attempt to reach you by phone first, and will send a text and email as well. The call may be displayed on your phone as "Eversense CGM". However, it will come from a number you are unfamiliar with, so be sure to check your voicemail box. The email from our representative will come from an @ascensia.com email address. If you haven’t received any email communications from our team within a few days, please check the spam folder in your email account.
Looking forward to getting in touch with you!
Unfortunately, based on the insulin therapy regimen or insurance information you provided, you may not be eligible for Eversense E3 CGM. In order to qualify, you must be on multiple daily doses of insulin.
If you do not have insurance, or if your insurance carrier does not cover Eversense E3 CGM, our PASS Program may help make Eversense E3 more accessible.
If you have any questions, please reach out to 1-844-736-7348.
If you're on insulin, you might greatly benefit from Eversense. After completing the form below, an Eversense representative will be in touch to discuss eligibility, coverage and next steps.
See how Eversense changed Troy’s life in this mini-documentary style video, which was produced for Ascensia by BBC StoryWorks Commercial Productions.
† The offers above only apply to the cost of the sensor and transmitter or sensor only. They do not cover the cost of the insertion procedure. Limitations and Restrictions may apply. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which patient out-of-pocket costs exceed what is detailed in INTRO and ONGOING offers.
* Up to 6 months
**There is no glucose data generated when the transmitter is removed
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider
1. Deiss D., et al. (2020). Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 22(1);48-52. DOI: 10.1089/dia.2019.0159.
2. Eversense E3 User Guide.